A decent showing for Pfizer/Roche in haemophilia sets up a rivalry with Uniqure/CSL, and a smattering of deals get done before the year end – and before JP Morgan.
Promising but early data with OTL-201 could see the group compete against the likes of Ultragenyx and Lysogene.
The approval is good for CSL, and better for Uniqure.
Immunogen and Uniqure are also set for Pdufa conclusions.
Bluebird’s gene therapy is to be launched in the US priced $2.8m per patient, but can the company tread the cautious path to profitability?